Skip to content

Expanding the cohort study of HIV-1-negative MSM and HIV-infected population

Expanding the cohort study of HIV-1-negative MSM and HIV-infected population

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1800016753
Enrollment
Unknown
Registered
2018-06-21
Start date
2018-07-01
Completion date
Unknown
Last updated
2020-08-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HIV/AIDS

Interventions

HIV negative Group:Free Condoms
HIV-infected group:Free Condoms

Sponsors

The First Affiliated Hospital, China Medical University
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: HIV negative Group: Men who attended the sites during the study period, had sex with men (oral and/or anal) within last six month, aged 18-65 years old, never being tested as HIV positive before, and provided written informed consent were recruited at the scheduled sites. HIV-infected group: 1. Long-term non-progress (LTNP) or Slow progress (SP) patient: Haven't been receiving HAART treatment; with HIV infection more than 10 years; more than 500 CD4+T cells per microliter and are stable; 2. Long-term non-progressors(LTNP) or Viremia Controller (VC) cohort: The HIV-positive without HAART treatment within 1 year and having the viral load of less than 2000 copy per milliliter for 3 times consecutively (each interval is more than 3 months); 3. Typical Progressed (TP) cohort: The HIV-positive that havent been receiving HAART treatment, except for the SP and VC.

Exclusion criteria

Exclusion criteria: HIV negative Group: 1. Unwilling to sign informed consent; 2. Unwilling to provide blood samples; 3. Those who do not wish to participate in the follow-up are withdrawn from the queue; 4. During cohort follow-up who become HIV seroconversion; HIV-infected group: 1. Patients who participate in any other HIV intervention study or experimental drug study; 2. Patients with mental retardation or cannot communicate with their doctors; 3. Serious alcoholics; 4. Not of Chinese nationality.

Design outcomes

Primary

MeasureTime frame
HIV antibody;

Secondary

MeasureTime frame
HSV-2;Syphilis;

Countries

China

Contacts

Public ContactHong Shang

Key Laboratory of AIDS Immunology of National Health and Family Planning Commission, Department of Laboratory Medicine, The First Affiliated Hospital, China Medical University

hongshang100@hotmail.com+86 15002476278

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026